[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
February 1, 2008

Severe Purpuric Xerotic Dermatitis Associated With Gefitinib Therapy

Arch Dermatol. 2008;144(2):269-270. doi:10.1001/archdermatol.2007.53

Gefitinib (Iressa; AstraZeneca, London, England) has been used in the treatment of non–small cell lung cancer (NSCLC).1 The cutaneous toxic effects associated with epidermal growth factor receptor (EGFR) inhibitors are follicular eruption, paronychia, and xerosis.2-4 Herein, we describe 3 patients with reticular erythematous eruptions on the lower extremities associated with gefitinib.